Wound Management Technologies Reports Record Preliminary Financial Results For Q1 Ended March 31, 2016

ADDISON, TX / ACCESSWIRE / April 19, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced record preliminary financial and operating results for Q1 ended March 31, 2016.

Quarter Ended March 31, 2016

Revenues were approximately $1,094,500 for the three months ended March 31, 2016, and $707,469 for the three months ended Dec 31, 2015. This increase is approximately 55%, attributable to increases in the surgical product line coupled with the results of focusing on sales.

The Company plans a full release of its results for the three months ended March 31, 2016 on or about the middle of May 2016.

“We are pleased with the continued growth in our sales and distribution team and with the traction they are getting in the marketplace,” said Deborah Jenkins Hutchinson, President. “Our CellerateRX Surgical product is being used by additional surgical specialties with impressive results. Our customer base is growing across the country as new distributors create sales in additional hospitals and surgery centers.”

“Our focus remains solidly on sales and on supporting our sales channel,” she continued. “We look forward to continuing to show solid revenue growth.”

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The Resorbable Orthopedic Products subsidiary owns a multi-faceted bone wax and bone void filler patent and markets products in the $1.5B biomaterials market and is anticipating new revenues from HemaQuell Resorbable Bone Wax. For more information visit our newly updated website, www.wmgtech.com.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
972-218-0935
info@wmgtech.com

SOURCE: Wound Management Technologies, Inc.

ReleaseID: 438946